Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $145 from $87 and keeps a Buy rating on the shares. Despite the “tremendous outperformance of shares,” the firm still sees room for upside, not just from the Phase 2 TOIVA proof-of-concept trial data for QTORIN rapamycin 3.9% in cVMs due in mid-December but also the “numerous value-creating programs” it sees coming from the QTORIN platform, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Palvella Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Palvella Therapeutics price target raised to $148 from $90 at Canaccord
- Buy Rating Affirmed for Palvella Therapeutics: QTORIN Platform Expansion and Potential FDA Approval Drive Optimism
- Palvella Therapeutics Expands Rare Disease Pipeline